Skip to main content
Springer logoLink to Springer
. 2021 Mar 24;100(7):1919. doi: 10.1007/s00277-021-04503-1

Correction to: High efficacy of BGD (bendamustine, gemcitabine, and dexamethasone) in relapsed/refractory Hodgkin lymphoma

Ryszard Swoboda 1, Sebastian Giebel 1, Wanda Knopińska-Posłuszny 2, Ewa Chmielowska 3,4, Joanna Drozd-Sokołowska 5, Ewa Paszkiewicz-Kozik 6, Waldemar Kulikowski 7, Michał Taszner 8, Włodzimierz Mendrek 1, Jacek Najda 1, Tomasz Czerw 1, Magdalena Olszewska-Szopa 9, Anna Czyż 9, Agnieszka Giza 10, Wojciech Spychałowicz 11, Edyta Subocz 12, Paweł Szwedyk 13, Aleksandra Krzywon 14, Agata Wilk 14, Jan Maciej Zaucha 8,
PMCID: PMC8496665  PMID: 33760951

Correction to: Annals of Hematology

10.1007/s00277-021-04448-5

In the above-mentioned article, the affiliation of one author Magdalena Olszewska-Szopa is not correct. It is presented as 8 (Department of Hematology and Transplantology, Medicl University of Gdańsk). It should be 9 (Department of Hematology, Blood Neoplasms and Bone Marrow Transplantation, Wrocław Medical University, Wrocław, Poland).

The original article has been corrected.

Footnotes

The online version of the original article can be found at 10.1007/s00277-021-04448-5

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


Articles from Annals of Hematology are provided here courtesy of Springer

RESOURCES